Economic and regulatory considerations in pharmacogenomics for drug licensing and healthcare.
Shah
Jai
J
Department of Social Policy, London School of Economics and Political Science, and is now at the Canadian Institutes of Health Research, 410 Laurier Avenue West (11th Floor), Ottawa, Ontario K1A 0W9, Canada. jshah@cihr-irsc.gc.ca
D002170:Canada; D003362:Cost-Benefit Analysis; D017277:Drug Approval / Q000191:economics* / Q000331:legislation & jurisprudence*; D033161:Government Regulation; D019981:Health Care Sector / Q000331:legislation & jurisprudence*; D007880:Legislation, Drug / Q000191:economics*; D016365:Liability, Legal / Q000191:economics; D008004:Licensure / Q000191:economics* / Q000331:legislation & jurisprudence*; D009965:Orphan Drug Production / Q000191:economics / Q000331:legislation & jurisprudence; D010597:Pharmacogenetics / Q000191:economics* / Q000331:legislation & jurisprudence*; D014481:United States